From center to edge: Prognostic implications of spatial metabolic heterogeneity, normalized hotspot-to-centroid and perimeter distance, on PET imaging. A systematic review and meta-analysis.

Eur J Nucl Med Mol ImagingJul 10, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Sajjad Sadeghpour, Ramin Sadeghi, Atena Aghaee et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic value of PET-derived spatial radiomic features, specifically normalized hotspot-to-centroid (NHOC) and normalized hotspot-to-perimeter (NHOP) distances, in cancer patients. The analysis included 1,496 patients across ten studies, revealing that elevated NHOC was significantly associated with worse overall survival (HR of 2.313, 95% CI [1.418, 3.775], p = 0.001).

Key findings

  • Elevated NHOC was associated with worse overall survival (HR of 2.313, 95% CI [1.418, 3.775], p = 0.001).
  • In lung cancers, NHOC showed a strong association with overall survival (HR of 2.864, 95% CI [2.018, 4.063], p < 0.001).
  • NHOP decrease indicated a non-significant trend toward poorer progression-free survival (HR = 2.92, 95% CI: 0.71-11.92).
  • Predictive models based on NHOC demonstrated moderate performance with an AUC up to 0.77.

Why it matters

Understanding tumor heterogeneity through PET-derived biomarkers like NHOC can enhance prognostic assessments in oncology, potentially guiding treatment decisions and improving patient outcomes.

Source

Published in Eur J Nucl Med Mol Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.